SCHEDULE 13G/A: AWM Investment Company Reports 9.99% Stake in Oncocyte Corp

AWM Investment Company, Inc. has filed an amended Schedule 13G, disclosing a 9.99% beneficial ownership stake in Oncocyte Corp as of March 31, 2025.

Summary

• AWM Investment Company, Inc. (AWM) reported beneficial ownership of 2,857,069 shares of Oncocyte Corp common stock.
• This represents 9.99% of the outstanding common stock of Oncocyte Corp.
• AWM, as an investment adviser, holds sole voting and dispositive power over these shares.
• The shares are held across four funds: Special Situations Cayman Fund, L.P., Special Situations Fund III QP, L.P., Special Situations Private Equity Fund, L.P., and Special Situations Life Sciences Fund, L.P.
• The reported beneficial ownership includes common stock, pre-funded warrants, and warrants, with the exercise of warrants limited to maintain beneficial ownership below 9.99% of outstanding shares.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant, passive ownership stake by an institutional investor. It doesn't contain positive or negative news about the company's operations or financials, but the continued holding of a large stake by a professional investment firm can be seen as a neutral to slightly positive signal of confidence.

Positives

• A significant institutional investor, AWM Investment Company, Inc., maintains a substantial stake (9.99%) in Oncocyte Corp, indicating continued confidence.
• The filing confirms the investment is held in the ordinary course of business, not for control-influencing purposes, suggesting a passive, long-term investment stance.

Risks

• The beneficial ownership percentage is capped at 9.99% due to warrant exercise limitations, which could restrict AWM's ability to increase its stake through warrant conversion beyond this threshold.

Future Outlook

NA

Industry Context

This filing indicates continued institutional investment interest in Oncocyte Corp, a company operating in the healthcare diagnostics sector. Such filings are common for investment firms holding significant, passive stakes in publicly traded companies, reflecting their portfolio allocation strategies rather than specific operational insights into the issuer.

Comparison to Industry Standards

• This Schedule 13G filing is a standard disclosure for institutional investors holding over 5% of a company's stock, aligning with SEC regulations.
• AWM Investment Company, Inc.'s reported 9.99% stake in Oncocyte Corp is a significant, but passive, position, typical for investment advisers managing various funds.
• There are no specific comparable companies or projects mentioned in this filing to assess against industry benchmarks, as the document focuses solely on ownership disclosure.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially offering some stability or confidence from a large investor's continued position.

Key Dates

Recommendation

Keywords

Oncocyte Corp, AWM Investment Company, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Institutional Investor, SEC Filing, Biotechnology, Healthcare Diagnostics